Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? [0.03%]
肺癌患者中的补充和替代医学：一个被忽视的现象吗？
O Micke,J Büntzel,K Kisters et al.
O Micke et al.
Study on the use of complementary and alternative medicine (CAM) in lung cancer patients has been widely neglected. Therefore, we initiated a study on the use of CAM in lung cancer patients in addition to radiation treatment. Overall, 120 p...
Alexander Schmittel
Alexander Schmittel
Small cell lung cancer is a highly proliferative tumor with the potential of early hematogeneous spread. At the time of first diagnosis more than 80% of patients present with distant metastases. Although response rate to chemotherapy is hig...
B J Slotman
B J Slotman
Small cell lung cancer is an aggressive form of lung cancer with a poor prognosis. Most patients present with extensive stage of the disease. To reduce the high risk of brain metastases, prophylactic cranial irradiation has been shown to be...
Branislav Jeremic,Francesc Casas,Luhua Wang et al.
Branislav Jeremic et al.
Patients with extensive disease small cell lung cancer (ED-SCLC) represent approximately one-third of all SCLC patients. For these patients, chemotherapy (CHT) is the standard treatment of choice. With CHT given alone, however, there is not...
Dirk de Ruysscher
Dirk de Ruysscher
Limited disease small cell lung cancer (LD-SCLC) is a heterogeneous disease, not only for its clinical behavior, but also for is anatomical extension. In very rare, early cases, LD-SCLC might be treated with surgery and chemotherapy, but as...
Radiotherapy [0.03%]
放射治疗
Irenäus A Adamietz
Irenäus A Adamietz
The intrathoracic growth of the tumor causes several severe symptoms as cough, dyspnea, chest pain, hemoptysis, hoarseness, anorexia/nausea, and dysphagia. In patients with manifest or threatening symptoms radiotherapy (RT) as an effective ...
Robert Pirker,Wilma Minar
Robert Pirker
Patients with advanced NSCLC receive palliative chemotherapy with platinum-based doublets. Cisplatin-based doublets are preferred in patients with good performance status, whereas carboplatin-based protocols are preferred in patients with i...
Martin Stuschke,Christoph Pöttgen
Martin Stuschke
Hyperfractionation and hypofractionation combined with acceleration have been investigated in stage I-III NSCLC patients. In stage I tumors, hypofractionated radiation schedules given with highly conformal stereotactic body radiotherapy (SB...
Stefan Höcht,Jürgen Heide,Ronald Bischoff et al.
Stefan Höcht et al.
Adjuvant radiotherapy following radical surgery in NSCLC has long been a matter of debate. The pros and cons have all been discussed thoroughly and the data existing due to their partial outdated nature in respect of the diagnostic and ther...
Monika Serke
Monika Serke
Evidence clearly supports adjuvant chemotherapy following resection in patients with stage II or III non-small cell lung cancer (NSCLC). Based on 3 landmark studies, adjuvant chemotherapy has become standard in completely resected NSCLC sta...